Close X
Attorney Spotlight

What colorful method does Claire Miley use to keep up with the latest healthcare regulations as they relate to proposed transactions? Find out more>

Search

Close X

Experience

Search our Experience

Experience Spotlight

On December 1, 2016, Parker Hannifin Corporation and CLARCOR Inc. announced that the companies have entered into a definitive agreement under which Parker will acquire CLARCOR for approximately $4.3 billion in cash, including the assumption of net debt. The transaction has been unanimously approved by the board of directors of each company. Upon closing of the transaction, expected to be completed by or during the first quarter of Parker’s fiscal year 2018, CLARCOR will be combined with Parker’s Filtration Group to form a leading and diverse global filtration business. Bass, Berry & Sims has served CLARCOR as primary corporate and securities counsel for 10 years and served as lead counsel on this transaction. Read more here.

CLARCOR
Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Securities Law Exchange BlogSecurities Law Exchange blog offers insight on the latest legal and regulatory developments affecting publicly traded companies. It focuses on a wide variety of topics including regulation and reporting updates, public company advisory topics, IPO readiness and exchange updates including IPO announcements, M&A trends and deal news.

Read More >

Bass, Berry & Sims Recognized by The M&A Advisor for Transaction of the Year

November 24, 2014

Nashville, Tenn., (November 24, 2014) - Bass, Berry & Sims PLC has been recognized by The M&A Advisor for the firm's work on behalf of AmSurg Corp. (NASDAQ: AMSG) in connection with its July 2014 acquisition of Sheridan Healthcare Inc.

2014 M&A Advisor Award WinnerBass, Berry & Sims received the "M&A Deal of the Year" award in the "Healthcare/Life Sciences Deal of the Year (Over $250MM)" category as part of the 13th Annual M&A Advisor Awards. The Bass, Berry & Sims team was led by Chair of the firm's Healthcare Practice Jim Jenkins and included a team of attorneys from various disciplines that coordinated and completed healthcare regulatory, corporate, real estate, benefits and labor due diligence; negotiated all related deal documents; and handled the related SEC filings required to be made by AmSurg. The firm also represented AmSurg in its common stock, preferred stock and senior notes offerings as well as entering into a new credit facility.

The M&A Advisor reported that more than 130 nominees, representing more than 600 companies, became finalists for this year's awards. An independent judging committee of 11 top M&A experts determined the ultimate recipients of the awards. The awards were announced at the 13th Annual M&A Advisor Awards Gala on November 17 in New York, NY.

About The M&A Advisor
Since 1998, The M&A Advisor has been presenting, recognizing the achievement of and facilitating connections between the world's leading mergers and acquisitions, financing and turnaround professionals with a comprehensive range of services, including M&A SUMMITS, M&A AWARDS, M&A CONNECTS™, M&A LINKS™, MandA.TV and M&A MARKET INTEL™. For more information, please visit www.maadvisor.com.

About Bass, Berry & Sims PLC
With more than 200 attorneys representing numerous publicly traded companies and Fortune 500 businesses, Bass, Berry & Sims has been involved in some of the largest and most significant litigation matters and business transactions in the country. For more information, visit www.bassberry.com.


Related Professionals

Related Services

Notice

Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.